{"entity":{"type":"insider","cik":"0001743881","url":"/insider/0001743881","json_url":"/insider/0001743881.json","name":"BridgeBio Pharma, Inc.","name_source":"as-filed","also_issuer":true,"cross_url":"/issuer/0001743881"},"coverage_statement":{"n_transactions":16,"n_filings":9,"first":"2018-06-26","last":"2021-01-26","span_basis":"filed_date"},"name_variants":[{"name":"BridgeBio Pharma, Inc.","source":"filing","n_filings":3,"first_seen":"2019-05-29","last_seen":"2021-01-26"},{"name":"BridgeBio Pharma LLC","source":"filing","n_filings":6,"first_seen":"2018-06-26","last_seen":"2018-12-13"}],"transactions":[{"id":4759342,"accession":"0000899243-21-003286","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-003286","line_url":"/filing/0000899243-21-003286#line-1","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma, Inc.","owner_display_name":"BridgeBio Pharma, Inc.","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14428836.0,"shares_display":"14,428,836","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-26","filed_date":"2021-01-26","scope":"insider"},{"id":7775721,"accession":"0000899243-19-019337","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-019337","line_url":"/filing/0000899243-19-019337#line-1","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma, Inc.","owner_display_name":"BridgeBio Pharma, Inc.","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":882353.0,"shares_display":"882,353","price_per_share":29.9005,"price_display":"29.90","price_state":"stated","total_value":26382795.8765,"total_display":"26,382,795.88","total_whole":"26,382,796","shares_owned_after":24575501.0,"shares_owned_after_display":"24,575,501","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-07-03","filed_date":"2019-07-08","scope":"insider"},{"id":8049980,"accession":"0000899243-19-015088","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-015088","line_url":"/filing/0000899243-19-015088#line-1","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma, Inc.","owner_display_name":"BridgeBio Pharma, Inc.","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1103848.0,"shares_display":"1,103,848","price_per_share":25.93,"price_display":"25.93","price_state":"stated","total_value":28622778.64,"total_display":"28,622,778.64","total_whole":"28,622,779","shares_owned_after":23693148.0,"shares_owned_after_display":"23,693,148","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-24","filed_date":"2019-05-29","scope":"insider"},{"id":9204614,"accession":"0000899243-18-030928","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-030928","line_url":"/filing/0000899243-18-030928","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40653.0,"shares_display":"40,653","price_per_share":13.333905246845251,"price_display":"13.33","price_state":"stated","total_value":542063.25,"total_display":"542,063.25","total_whole":"542,063","shares_owned_after":22589300.0,"shares_owned_after_display":"22,589,300","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-10","filed_date":"2018-12-13","scope":"insider","n_lines":2},{"id":6898473,"accession":"0000899243-18-030738","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-030738","line_url":"/filing/0000899243-18-030738","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40653.0,"shares_display":"40,653","price_per_share":13.333905246845251,"price_display":"13.33","price_state":"stated","total_value":542063.25,"total_display":"542,063.25","total_whole":"542,063","shares_owned_after":22586636.0,"shares_owned_after_display":"22,586,636","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-10","filed_date":"2018-12-12","scope":"insider","n_lines":2},{"id":9204612,"accession":"0000899243-18-030927","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-030927","line_url":"/filing/0000899243-18-030927","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41174.0,"shares_display":"41,174","price_per_share":13.98957497449847,"price_display":"13.99","price_state":"stated","total_value":576006.76,"total_display":"576,006.76","total_whole":"576,007","shares_owned_after":22548647.0,"shares_owned_after_display":"22,548,647","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-07","filed_date":"2018-12-13","scope":"insider","n_lines":2},{"id":6647360,"accession":"0000899243-18-030596","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-030596","line_url":"/filing/0000899243-18-030596","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41174.0,"shares_display":"41,174","price_per_share":13.98957497449847,"price_display":"13.99","price_state":"stated","total_value":576006.76,"total_display":"576,006.76","total_whole":"576,007","shares_owned_after":22543787.0,"shares_owned_after_display":"22,543,787","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-07","filed_date":"2018-12-10","scope":"insider","n_lines":2},{"id":9204610,"accession":"0000899243-18-030927","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-030927","line_url":"/filing/0000899243-18-030927#line-1","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":38970.0,"shares_display":"38,970","price_per_share":13.34,"price_display":"13.34","price_state":"stated","total_value":519859.8,"total_display":"519,859.80","total_whole":"519,860","shares_owned_after":22507473.0,"shares_owned_after_display":"22,507,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-06","filed_date":"2018-12-13","scope":"insider"},{"id":6647355,"accession":"0000899243-18-030596","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-030596","line_url":"/filing/0000899243-18-030596#line-1","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":38970.0,"shares_display":"38,970","price_per_share":13.34,"price_display":"13.34","price_state":"stated","total_value":519859.8,"total_display":"519,859.80","total_whole":"519,860","shares_owned_after":22507473.0,"shares_owned_after_display":"22,507,473","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-06","filed_date":"2018-12-10","scope":"insider"},{"id":6436528,"accession":"0000899243-18-030324","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-030324","line_url":"/filing/0000899243-18-030324#line-2","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1103848.0,"shares_display":"1,103,848","price_per_share":14.01,"price_display":"14.01","price_state":"stated","total_value":15464910.48,"total_display":"15,464,910.48","total_whole":"15,464,910","shares_owned_after":22468503.0,"shares_owned_after_display":"22,468,503","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-05","filed_date":"2018-12-06","scope":"insider"},{"id":6436523,"accession":"0000899243-18-030324","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-18-030324","line_url":"/filing/0000899243-18-030324#line-1","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1750000.0,"shares_display":"1,750,000","price_per_share":15.5,"price_display":"15.50","price_state":"stated","total_value":27125000.0,"total_display":"27,125,000.00","total_whole":"27,125,000","shares_owned_after":21364655.0,"shares_owned_after_display":"21,364,655","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-12-03","filed_date":"2018-12-06","scope":"insider"},{"id":6035262,"accession":"0000899243-18-018143","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-18-018143","line_url":"/filing/0000899243-18-018143#line-3","is_derivative":false,"issuer_cik":"0001731831","issuer_name":"Eidos Therapeutics, Inc.","issuer_ticker":"EIDX","issuer_name_source":null,"issuer_url":"/issuer/0001731831","owner_cik":"0001743881","owner_name":"BridgeBio Pharma LLC","owner_display_name":"BridgeBio Pharma LLC","owner_url":"/insider/0001743881","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":17000000.0,"total_display":"17,000,000.00","total_whole":"17,000,000","shares_owned_after":19614655.0,"shares_owned_after_display":"19,614,655","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-06-22","filed_date":"2018-06-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":11,"open_market":true},{"code":"S","label":"Open-market sale","n":5,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001731831","name":"Eidos Therapeutics, Inc.","url":"/issuer/0001731831","role":"Ten percent owner","n_filings":9,"first_seen":"2018-06-26","last_seen":"2021-01-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001743881","retrieved_at":"2026-08-27T22:18:07+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}